Is chemoimmunotherapy a game changer in the treatment of locally advanced head and neck squamous cell carcinoma?

Autor: Masuda M; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Nagata R; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Hara H; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Kuroki K; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Sato K; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Rikimaru F; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Toh S; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan., Higaki Y; Department of Head and Neck Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan.
Jazyk: angličtina
Zdroj: Clinical case reports [Clin Case Rep] 2021 Sep 22; Vol. 9 (9), pp. e04793. Date of Electronic Publication: 2021 Sep 22 (Print Publication: 2021).
DOI: 10.1002/ccr3.4793
Abstrakt: Pembrolizumab and chemotherapy (chemoimmunotherapy) were administered to 2 head and neck squamous cell carcinoma (HNSCC) patients with extremely advanced local tumors and distant metastases with palliative intent. However, they demonstrated strikingly good responses and achieved remission. Expanded application of induction chemoimmunotherapy may be useful for locally advanced HNSCC.
Competing Interests: We have nothing to disclose.
(© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje